Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ImmuPharma says pre-clinical study points to other indications for lead drug

Currently being developed to treat lupus, peptide P140 may hold the potential to treat another painful autoimmune disease
vials be processed
The findings were encouraging for a drug that's already known to be safe and well tolerated

Pre-clinical work by ImmuPharma PLC (LON:IMM) on P140, the peptide currently being developed as Lupuzor for the treatment of people with lupus, reveals it may have other potential indications.  

The company's co-founder, Professor Sylviane Muller, and her team believe the drug could be deployed to treat an autoimmune disease called chronic inflammatory demyelinating polyneuropathy, or CIDP.

This a condition where medication is currently lacking and which is characterised by fatigue, diminished or absent tendon reflexes and sensory deficits, usually starting in the hands and feet.

CLICK HERE: For the full announcement 

The results of the pre-clinical study have been published in the Journal of Autoimmunity.

"Over the last couple of years we have provided further evidence of the role the P140 peptide can take in the potential treatment of other autoimmune diseases in addition to Lupus," said Muller.

"We are delighted that these results demonstrate positive pre-clinical data in a murine model of CIDP, which has no available disease-specific treatment.  We look forward to providing a further update on the progress of our CIDP programme in due course."

 

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
cancer cells from taken by an electron microscope
March 13 2018
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
leg bones
March 31 2018
"We are now in the position of really trying to kick on in 2018"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use